Miglustat en es it fr

Miglustat Brand names, Miglustat Analogs

Miglustat Brand Names Mixture

  • No information avaliable

Miglustat Chemical_Formula


Miglustat RX_link


Miglustat fda sheet

Miglustat FDA

Miglustat msds (material safety sheet)

Miglustat Synthesis Reference

No information avaliable

Miglustat Molecular Weight

219.278 g/mol

Miglustat Melting Point

169 - 172 oC

Miglustat H2O Solubility

Highly soluble in water (>1000 mg/mL as a free base).

Miglustat State


Miglustat LogP


Miglustat Dosage Forms

Capsules (100-mg) for oral administration

Miglustat Indication

For the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to constraints such as allergy, hypersensitivity, or poor venous access).

Miglustat Pharmacology

Miglustat is an N-alkylated imino sugar, a synthetic analogue of D-glucose. Miglustat is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first step in the synthesis of most glycosphingolipids.

Miglustat Absorption

Mean oral bioavailability is 97%.

Miglustat side effects and Toxicity

Miglustat has been administered at doses of up to 3000 mg/day (approximately 10 times the recommended starting dose administered to Gaucher patients) for up to six months in Human Immunodeficiency Virus (HIV)-positive patients. Adverse events observed in the HIV studies included granulocytopenia, dizziness, and paresthesia. Leukopenia and neutropenia have also been observed in a similar group of patients receiving 800 mg/day or above.

Miglustat Patient Information

Miglustat Organisms Affected

Humans and other mammals